SCHEMBL11945003

SCHEMBL11945003

CCCCCCCOc1c(N2CCN(S(=O)(=O)Cc3ccc(C(F)(F)F)cc3)CC2)cnn(-c2ccccc2)c1=O

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.42
▸ DCTPP1 Q9H773 3/20 0.42
▸ HSD11B1 P28845 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.36
▸ NPBWR1 P48145 2/20 0.36
▸ EGLN1 Q9GZT9 1/20 0.36
▸ MCHR1 Q99705 1/20 0.36
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943866 0.92 MAPT (0.56) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11943885 0.92 MAPT (0.48) MAPTALDH1A1DCTPP1HSD11B1LMNA
SCHEMBL11944989 0.91 MAPT (0.52) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11944987 0.90 MAPT (0.57) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11943867 0.87 MAPT (0.64) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11943871 0.87 MAPT (0.55) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11945004 0.87 MAPT (0.49) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11944004 0.85 MAPT (0.47) MAPTALDH1A1DCTPP1HSD11B1LMNA
SCHEMBL11943879 0.85 MAPT (0.52) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11943869 0.85 MAPT (0.58) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885ALDH1A1 2437/4885DCTPP1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback